Strains of yellow fever virus isolated since I927 in Africa and the Americas, and strains derived from them, have been differentiated by the responses of mice of different ages to intraperitoneal (i.p.) or intracerebral (i.c.) infection. Infection, antibody conversion, protection and death have been presented on age-dose response phase diagrams that serve as in vivo 'fingerprints' for the differentiation of virus strains and their modifications through passage and selection. Correlations between marker characteristics are discussed in terms of the efficiency of infection, regulatory (pre-challenge) and protective (post-challenge) immunity, and the expression of virulence. The requirement in virus strain specification for the resolution of events on pathogenic and immunogenic pathways is discussed.
INTRODUCTION
The identity of a virus strain or variant is established by the pattern of its interactions with a range of responsive hosts. This essential basis for the control of vaccines and therapeutic strategies, or for the specification of infective agents as pathogenic or apathogenic, leads to a number of simplifying correlations. A first correlation is required of the responses of the principal host with those of model or indicator hosts. A second set of correlations may be sought between the phases of the virus-host interaction and the intrinsic characteristics of the infecting virus strain (molecular, serological, in vitro) or of the 'normal' host (genetics, stress, competence) .
All such studies require a specification in the virus-host interaction of such qualities as the efficiency of infection, expression of virulence, transmissibility, persistence and immunogenicity. Once the phases of the virus-host interaction have been sufficiently defined, correlations between hosts and with putative in vitro markers may be established.
The present studies with strains of yellow fever virus (YFV) were undertaken in an attempt to define the virus-host interaction and the differentiation of in vivo qualities.
METHODS
Virus strains. The strains of YFV used represent isolations made since I927 in Africa and the Americas. The YFV strains (Table 1) Table I . All strains were obtained at the lowest passage level available or as R. FITZGEORGE AND C.J. BRADISH long-passaged or selected-adapted material of particular interest as determined by previous studies. The small available quantities of most virus strains necessitated the use of one further suckling mouse brain passage (mi) in this laboratory to produce the working stocks listed. These were stored in minimal amounts of o'5 ml at -7o °C or in liquid nitrogen. The medium for storage and sample dilution throughout was Parker's medium I99 at pH 7"6 with T o % foetal calf serum. The stability of YFV infectivity during storage will be described elsewhere. It is evident from Table I that some strain passage histories are long and uncertain. The I7D vaccine strain of Theiler and co-workers (Lloyd et al. 1936; Theiler & Smith, ~937;  Strode, i95i ) is of exceptional interest in view of its production for over 4o years as the standard human yellow fever vaccine. The derivation of the t7 D vaccine strain from the 53rd passage of the Asibi strain (YI in Table I ) in monkeys is an important example of the changes with passage of some virulence/avirulence marker characteristics. This long course of'adaptation' is shown in Fig. I and could not be reproduced (Strode, I951).
Assay of r7D YFV infectivity in agar suspension of primary chick embryo cells. Of the strains of YFV considered here only the derivatives of the I7 D vaccine strain yielded plaques suitable for the efficient assay of virus infectivity in agar suspensions of primary chick embryo cells. Samples of virus or tissue suspensions to be titrated were diluted serially in medium I99 plus I o % foetal calf serum at pH 7"6. Amounts of o'5 ml were mixed with 2 × io 8 primary chick embryo cells in 2 ml of the same medium at 37 °C. After I5 min at 37 °C, 2"5 ml of i % agarose (Miles-Seravac Ltd.) in medium I99 at 44 °C were added and the whole rapidly poured into a 5 cm diam. Petri dish. Once set these were kept for 5 days at 37 °C in an atmosphere of air plus 5 ~o CO2. After flooding with o'oo5 % neutral red in physiological saline the clear t to 2 mm plaques were counted and the virus concentration per ml of initial sample calculated. Replicate estimates of p.f.u./ml correspond very closely with parallel estimates of suckling mouse i.c. LD~0 units.
Assay of neutralizing antibody activity. Various samples of human, rabbit and mouse antisera to strains of YFV were assayed for virus neutralizing activity by the plaque reduction procedure. Suspensions of primary chick embryo cells were used as with Semliki
Forest virus (Bradish et al. r97t ; Fitzgeorge & Bradish, 1973 ) and adjusted as above for the infectivity assay of I7D YFV. Neutralization indices (SNI) indicating the logarithm of the antibody activity or concentration were calculated as described by Bradish et al. 0962) .
For surveys of the neutralizing activities of up to Ioo samples a zone inhibition method was used. Here the agarose suspensions of primary chick embryo ceils were prepared with a constant confluence of about Iooo YFV 07D) plaques per 5 cm dish. After setting, 6 mm diam. holes were cut to receive o'o3 ml amounts of dilutions of the antisera to be assayed. After incubation for 5 days at 37 °C as above, the plates were stained and the serum neutralization indices (SNI) of the applied samples were indicated as proportional to the diameters of the circles of non-plaque formation that surrounded each sample hole. Standard antisera of known SNI were included in each test series.
Procedures in mice.
The mice used in this study were of strains Balb/C (inbred), AzG (limited outbred) and Porton (random outbred). Mice of defined ages (_+ lO%) in groups of five to ten were used for the titration of virus strain samples by the inoculation ofo.o25 ml intracerebrally (i.c.) or o-I ml intraperitoneally (i.p.) of graded serial tenfold dilutions in buffered physiological saline at pH 7"6. Paralysis was followed by death within 36 h and associated with a high brain infectivity due to YFV. Mice were therefore scored as dead (D) even if killed for tissue and blood sampling at the onset of frank paralysis.
According to virus strain, route and dose, the mice surviving to 14 or 2I days after primary infection were bled for assay of serum neutralizing activity and then lethally challenged by the inoculation i.c. of lo 4 p.f.u, in 0-o25 ml of the I7D.CI vaccine strain of YFV. Mice surviving for 14 to 2I days after virulent challenge were scored as protected (P). This category of protection was subdivided further according to the presence (P+) or absence (P-) of detectable neutralizing antibody activity at the time of challenge: thus P+ and Pindicate the incidence of protection in mice showing or lacking antibody conversion. Challenge and other controls were included at equal weight in every test (Bradish et ak I975) .
The infectivities of the virus strain samples used were assayed by direct plaque counting or by titration through the brains of suckling mice. Thus the input dose of potentially infective units was defined as p.f.u, or suckling mouse (SM) i.c. LDs0 units. This procedure follows that used for unadapted strains of VEE virus (Walder & Bradish, I975 , I979) which do not regularly form countable plaques.
Since mice of any age were equally sensitive to lethal i.c. infection by the present strains of YFV, the adult mouse i.c. LDs0 unit was used interchangeably with the suckling mouse i.c. LD~0 unit as a standard of potential infectivity.
Assessment of responses in mice. The scores in any test showing the incidence of mice dead (D), protected against lethal challenge (P+ or P-) or uninfected and susceptible (S), enable a number of 5o% response-doses to be calculated (Reed & Muench, I938) and related as a ratio to actual inputs of potentially infective units. Thus the number of input infective units required for the LDs0 was estimated from the incidence of deaths (D) shown through the titration series. Similarly the number of input infective units required for antibody conversion in 50 0/0 of the test group was estimated from the incidence of detected neutralizing activity.
The number of input infective units required for infection in 50 0/0 of the test group (IDs0) was estimated from the total incidence of any detectable response to infection (primary death, protection, antibody synthesis and recovery of infective virus). This estimated ID~ corresponded with the P-D5o if significant protection was observed in the absence of detectable antibody activity.
Efficiency of infection for mice. As in studies with SFV & VEEV (Walder & Bradish, I975, I979) , the number of infective units required for the IDs0 in any test indicates the reciprocal of the efficiency of infection. Thus if Iooo p.f.u, are identified with the IDs0, then the efficiency of infection is only o.ool under these conditions and 99"9 ~o of input virus is eliminated before progressive replication or immune stimulation can occur. This efficiency of infection is independent of the outcome of infection as death or protection.
RESULTS

Response of mice to intraperitoneal infection
To characterize the response of A2G mice to i.p. infection, groups of seven to ten mice of defined age were inoculated with to a to io 4 infective units of the strains of YFV listed in Table I . Mice were scored for survival until death (D), protection against lethal challenge (P) or as primarily uninfected and susceptible (S). Except as noted below for the I7D vaccine strains, most mice were infected by the administered doses and showed either paralysis and death, or protection with (P+) or without (P-) detectable antibody conversion.
The results summarized in Fig. 2 show that the 0/0 mortalities decline sharply above a certain age at infection so that an age for 50 0/0 death: 50 ~o protection may be defined in each case. These critical ages at infection for the change from death to protection occur at about 3"5 days old for the I7D(A). CI vaccine strain at 9 to I2 days old for the majority of (Walder & Bradish, r975, 1979) , herpes simplex virus at (e) (see Discussion and Darlington & Granoff, 1973) , lymphocytic choriomeningitis virus at (a) (Lehmann-Grube, I97~) and the graft v. host reaction at (a) (Billingham & Brent, 1957 , 1959 . 
Responses of mice to intraeerebral infection
Although all of the strains of YFV listed in Table I are lethal for adult mice following i.e. infection, there is nevertheless a wide range of survival times before death. This is shown in Fig. 3 for 35-to 55-day-old A2G mice in relation to the number of LDs0 units administered in o'o25 ml. The strains D2 and D2.mr (Fig. 3 a, b ) kill mice most rapidly at 5 to 7 days whereas strain OI does not kill until I4 to I8 days after infection i.e. The remaining Y strains and I7D vaccine strains all kill mice within IO to I4 days ( Fig. 3 e) ; these results are not shown individually.
When the infectivity of the YFV strain D2 was reduced by antiserum from io 6 to Io 2 infective units per ml, the survival time in mice was only prolonged from about 7 to 9 days (Fig. 3 e) . Similarly, when the Y1 strain was inoculated i.e. as Io 1'~ LDs0 in the presence of IO 5 initial LDs0 of formalin-inactivated virus, the survival time was only prolonged from about Ix to 13 days (Fig. 3f ).
These results demonstrate that the survival time is a significant in vivo characteristic that is not greatly modified by considerable excess concentrations of inactivated or neutralized virus. Furthermore, the survival times following i.e. infection are only slightly shortened when infective doses increase (Fig. 3) . Similar survival times are maintained even when suckling mice are infected i.e. and in adult mice of other strains (Martin, I969; Darnell et aL I974) .
Relationships between in vivo characteristics
It is important to consider the functional relationships between the in vivo characteristics summarized in Fig. 2 and 3 . The age of mouse in days at infection for a response of 5o % death:5o% protection (from Fig. 2 ) is shown in Fig. 4 in relation to the survival time for adult mice following i.e. infection (from Fig. 3 
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vaccine strain of YFV conforms to the reciprocal relationship (Fig. 4) only when input doses in excess of Io 3 IDso are considered. The general relationship between the survival time following i.e. infection (Fig. 3 ) and the age for immunological maturation to the level required for protection i.p. (Fig. 2) indicates that even the i.e. infection in adult mice is regulated by an effective immunological feed-back. Thus the French 'viscerotropic' strain DI kills adult mice most slowly following i.c. infection and fails to kill even 9-day-old suckling mice following i.p. infection. Recent studies with distinct strains of VEE virus (Walder & Bradish, I979) have also shown that survival time and age-response characteristics are indicators of the balances between events on pathogenic and immunogenic pathways.
Relationships to tests in monkeys
The wide use of monkeys, particularly Macaea mulatta, for the assessment of the in vivo characteristics of virus strains prompts the comparison of the pathogenic-immunogenic balances in mice and monkeys under different conditions of infection. The early information summarized in Fig. I shows the responses of M. mulatta to i.c., i.s. (intraspinal) or i.p. inoculation of YFV strains on the passage-adaptation route between YI and the derived I7D vaccine (Table I ). This indication of the strain-route conditions provoking a response of 5o % death: 5o % protection may be compared with those summarized for mice of different ages in Fig. 2 . On this basis the 5o % death: 5o % protection responses of monkeys to a YFV strain inoculated i.c., i.s. or i.p. correspond with those of mice between 6 and I2 days old inoculated i.p. Thus, despite detailed differences in tissue tropism and cellular mechanism, the balances between pathogenic and immunogenic events that determine death or protection in monkeys can be paralleled closel3/in developing mice of the appropriate age at infection. This rationalization of distinct in vivo indicators in monkeys (i.e., i.s., i.p. ; Fig. I ) and in mice (i.e., i.p. ; Fig. 3 ) is shown in Fig. 4 and discussed later.
Dose-response relationships for z7D(A) strains of YFV
In view of the features (Fig. 4) shown by the important I7D vaccine strains of YFV, a more detailed study was made of the responses of mice of different ages to the i.p. admini, stration of graded doses. Mice of strain A2G were observed for sickness or paralysis for 21 to 35 days when they were bled for antibody and then challenged i.c. with iO p.f.u, of the I7D. CI strain of YFV. Thus host scores were available through graded doses of virus for estimations in mice of different ages of the p.f.u, required for 5o% lethality (LDs0), 5o% protection (PDs0 , IDs0) or for 5o % protection with (P+Ds0) or without (P-D~0) detectable antibody activity in serum.
The results (Fig. 5 ) for these several individual titrations through groups of seven to ten mice indicate that about io 3 p.f.u.i.p, are required for the LDs0 in 3-to 4-day-old mice. This rises rapidly to about ~o 6 p.f.u.i.p, for the LDs0 in mice of 2o days old or older and defines a steeply rising LDs0 age characteristic (Fig. 5 a) .
Estimations of the p.f.u, dose for protection in the absence of detectable antibody synthesis (P-D~0) show that I p.f.u.i.p, infects and protects mice up to 5 days old. This dose rises rapidly to the requirement for about IO p.f.u.i.p, for infection and protection at 2o days old (Fig. 5 c) . For both the 17D mouse passed (t 7D. m I) and CEC passed (i 7D. C l) strains the p.f.u, doses i.p. for detectable antibody synthesis (P+Ds0) were regularly about 3o-fold higher than the infecting-protecting dose (P-Ds0): this is shown by the response lines (b) and (e) in Fig. 5 .
Results for actual individual levels of serum antibody activity are not quoted in detail since mice were either strongly positive, with serum neutralization indices of 2"5 to 3"5, or clearly negative (SNI < I). Intermediate SNI levels were rare. Thus the incidence of positive antibody conversion to SNI 3 + 0"5 is shown by the P+Dso characteristic (Fig. 5b) . A consequence of this sharp dose-dependent switch from undetectable to strong stimulation of antibody synthesis is that these results do not depend upon the actual sensitivity of antibody activity detection. This applies throughout to A2G and Balb/C mice with many strains of YFV. The multiple dose-response characteristics of the type shown in Fig. 5 form a phase diagram or in vivo fingerprint by which virus strains may be identified by the pattern of interactions of pathogenic and immunogenic events. Thus zone D (Fig. 5 ) embraces the range of mouse ages and virus doses associated with paralysis and death and, as shown in Fitzgeorge & Bradish (I98O), the proliferation of virus in brain to high levels (lO 6 to lO s p.f.u./brain). The intermediate zone P+ indicates the range of ages and doses for which protection against virulent challenge and elimination of brain infectivity is also accompanied by high serum antibody activity. The zone P-indicates the range of age-dose conditions for which virus stimulation ensures protection against challenge but not the detectable synthesis of antibody. Virus doses for antibody conversion are about 3o-fold higher than those required for infection and protection. The lowest line (c) defines, through the age dependence of the IDs0 and P-Ds0, the efficiency of infection and of stimulation. In the zone S the mice are uninfected and normally susceptible to the virulent challenge. 
Response phase diagrams and the differentiation of virus strains
When parallel tests like those of Fig. 5 were made in A2G or Balb/C mice of defined ages with the YFV strains YI, DI and 02, the phase diagrams shown in Fig. 6 and 7 were obtained. The many distinctions between these patterns of responses to i.p. infection are demonstrated when the lines for the I7D.CI strain are superimposed upon the phase diagram for the YI (Asibi) strain (Fig. 6) . For the YI strain, mice younger than about I I days old died with paralysis and CNS involvement, whereas mice older than about 15 days were uniformly protected and showed no infectivity in tissues. In mice from I I to I5 days old infected i.p. by YI (Asibi), the pathogenic (LDs0) and immunogenic (IDs0, PD~0) presentations diverge rapidly due to the development of an efficient immunological regulation.
The differentiation of these typical strains of YFV is shown through several features of these superimposed phase diagrams (Fig. 6) . In Zone A the YI strain is lethal and the I7 D strain protective. In Zone B the YI strain is protective but the I7 D strains fail to infect. Evidently the efficiency of infection and rate of immune stimulation by the YI Asibi strain of YFV are significantly higher than those shown by the I7D vaccine strain. This emphasizes the critical interactions between events on pathogenic and immunogenic pathways that follow infection and stimulation by different strains of YFV.
This differentiation of response phase diagrams has been extended to the strains of virus listed in Table I and is shown for the extreme strains DI and D2 in Fig. 7 . Both of these strains show a higher efficiency of infection so that IO p.f.u.i.p, is a 5o% infective and protective dose even in mice of 3o days old or older. As for all of the strains tested (Fig. 5,  6 and 7) , an input dose of about 3o IDs0 or P-Dso is required before positive antibody stimulation can be detected in the majority of test mice. These DI and D2 strains of YFV show LD~0 characteristics (Fig. 7 ) that rise steeply with mouse age; for an i.p. dose of IO s'5 infective units the DI strain protects mice over 8 days old whereas the D2 strain continues to kill mice up to about 2i days old. This information (as for Fig. 2 ) indicates that these particular strains are most sensitively differentiated in mice of about I5 days old for which D2 is lethal but DI protective (zone A in Fig. 7) .
Appropriately selected tests based on the response phase diagrams (Fig. 5, 6 and 7) distinguish and differentiate each strain of YFV in terms of its age-dependent efficiency of infection, immune stimulation (IDs0 and PDs0 lines) or lethality (LDs0 lines). In most cases two strains of YFV may be differentiated as illustrated above, by more than one of these characteristics in different age-dose zones of the phase diagrams. It is particularly to be noted that any strain of YFV may be lethal or protective and may or may not stimulate vigorous antibody production, according to the age of mouse and virus dose administered.
DISCUSSION
The in vivo differentiations outlined in this paper show that efficiency of infection (IDs0 per infective units), expression of virulence, regulatory immunity (we-challenge) and protective immunity (post-challenge) are separate and dose-dependent qualities of the progressive virus-host interaction. These qualities have been resolved more clearly through titrations in mice of different ages and levels of immune competence.
The critical maturation changes that may occur in mice at definite ages of about 3, 7, I I and 20 days old influence these host responses to some but not all strains of YFV. A similar observation has been made for strains of SFV and VEEV (Walder & Bradish, I975, 1979) . The changes in mice at about 2 to 3 days old indicated by the graft v. host reaction and responses to LCM virus (Billingham & Brent, 1957 , 1959 Lehmann-Grube, 197t) Arising from these several in vivo criteria and their presentation as response phase diagrams (Fig. 5, 6 and 7), the strains of YFV virus may be differentiated as summarized in Table 2 . The last two columns quantify the efficiency of infection and the events on the immunogenic pathway that may subsequently modulate the expression of virulence signified through the first two columns. According to the strain of virus, there is a very wide range of efficiency of infection in young adult mice from about 3 to over IO 5 infective units per i.p. IDa0; the stimulation of vigorous antibody synthesis in AzG or Balb/C mice uniformly requires about 3o-fold higher doses of virus. Thus in all phase diagrams the P-Ds0 and P+Ds0 lines are separated by a distance of about 1.5 log dose units.
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An examination of Table z indicates, as for the phase diagrams, that the in vivo characteristics of LDs0-age relationship, survival time following i.c. infection and age for change of response to i.p. infection are mutually related (Fig. 2, 3 and 4) and distinct from the initiating efficiency of infection and stimulation (IDa0 and P+Dso, i.p.). This emphasizes the early divergence of the pathogenic and immunogenic pathways. The responses of monkeys to i.c., i.p. and i.s. infections by strains of YFV (Fig. 4) appear to parallel those of 6-to I2-day-old mice. This suggests that under appropriate conditions different hosts may show a similar interaction between events on pathogenic and immunogenic pathways. In view of the diversity of antibody and lymphocyte classes and their dynamic involvements with some virus strains and not others (Fig. z) , it is probable that the present operational approach to the resolution of in vivo pathways and interactions may allow correlations to be made between the responses of different hosts before each phase of host response can be interpreted in molecular, cellular or genetic detail.
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The strains of YFV of African origin (YI to YI8) are marginally and regularly different from those of S. American origin (Y25 to Y28). Thus African strains (Table 2) show a higher efficiency of infection and stimulation and may be more heterogeneous with respect to protection of mice (Fig. 2) . A greater antigenic range was noted by Clarke (196o) for African strains of YFV which showed an antibody-combining component not present in S. American strains.
Although the manipulations by which the strains DI, D2 and I7D have been derived (Table I, Fig. I ) are long and irreproducible, it is clear from the in vivo criteria summarized in Table 2 that these three strains illustrate different routes of variant selection from the parental 'Y' stock. The t7D vaccine strain appears as a selection or variant of greatly impaired efficiency of infection and stimulation yet unchanged capacity to involve the target site once infection is established. The DI and D2 strains, by contrast, show improved efficiency of infection and protection associated with enhanced (D2) or reduced (DI) involvement of the CNS. These distinct selections emphasize not only that changes in pathogenicity and immunogenicity may be independent but that, as here, separate in vivo characteristics may be required for identification. The recent review by Kantoch (I978) cites several cases in which markers and assessments of vaccine immunogenicity are unrelated to the markers and assessments of vaccine pathogenicity (attenuation). Clearly an improved quantification and resolution of host-response pathways to any series of virus strains must precede their correlation with putative in vitro or molecular markers.
A recent summary of the responses of human volunteers to infection by a stabilized ITD(A) YFV vaccine (Freestone et al. I977 ) indicated a subcutaneous dose of about 4o infective units (p.f.u.) for 50% antibody conversion on the 28th day. Positive antibody responses showed a serum neutralization index of about 3 and 2.8 for IO ~ and ~o ~ infective units, respectively. Natural primary infections by 'wild' strains of YFV usually show specific seroconversion in man in about 3 weeks with levels rising in the following weeks (Theiler & Downs, I973) . During the earlier acute phases of invasion and stimulation human sera are rarely antibody positive. Mason et al. (I973) have studied the responses of Rhesus monkeys to I7D intramuscular vaccination followed by virulent challenge 2o weeks later by iooo infective units subcutaneously of the YI (Asibi) strain of YFV. The 5o % protective dose was about 2o infective units (suckling mouse i.c. LDs0 ) and only monkeys later shown to be protected had positive serum neutralization indices of about 2-5 from the 4th to the 2oth week. The elevation of these serum neutralization indices to about 5 within 2 weeks following challenge demonstrated the relatively poor immunogenicity of the I7 D vaccine which failed to stimulate some compartments that then responded rapidly to the 'wild' challenge. These studies generally show that man and monkeys are efficiently infected by less than 2o to 4o infective units of the I7D vaccine strain of YFV but that the stimulation of antibody synthesis or protection may be relatively slow or inefficient even at doses of up to ~o 5 infective units. Although the range of test conditions in such studies precludes closer comparisons, it is probable that the mouse can be used as a much more sensitive indicator of strain differences and of the critical phases of the virus-host interaction that now limit the standardization of vaccine heterogeneity, pathogenicity and immunogenicity.
